PODESTA GROUP, INC. for MILLENNIUM PHARMACEUTICALS INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| ANNE MARIE POLAK | — |
| THOMAS B SPARKMAN | — |
| DONNI TURNER | — |
Budget/Appropriations BUD
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011 H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
| DONNI TURNER | — |
Medicare/Medicaid MMM
Medicare Issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-31 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290 H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| ANNE MARIE POLAK | — |
| THOMAS B SPARKMAN | — |
| DONNI TURNER | — |
Pharmacy PHA
Drug Safety/Pedigree Bills P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| ANNE MARIE POLAK | — |
| THOMAS B SPARKMAN | — |
Copyright/Patent/Trademark CPT
S. 515 Patent Reform Act of 2009 S. 610 Patent Reform Act of 2009 H.R. 1260 Patent Reform Act of 2009
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.